



Program Scientific Spring Meeting NVKF&B

17 April 2026: Gorlaeus Building, University Leiden

09.00 h Registration and coffee
 09.30 h Welcome and introduction – Room C4/5
 09.35 h Plenary session Room C4/5

Innovations in drug development – Room C4/5

09.35 h	Prof. dr. Gerard van Westen – Artificial Intelligence-driven drug development: from molecular design to clinical application
10.05 h	Dr. Rosa de Groot – Navigating the journey of CAR-T cell therapy trials

10.35 h Coffee Break – Restaurant
 11.00 h Parallel oral presentation sessions

Session 2	Oncology – Room C4/5
11.00	Niels Heersche - Survival outcomes after UGT1A1 genotype-guided dosing of irinotecan: Results of a multicentre survival analysis
11.15	Sofia Peeters - Severe toxicity risk of UGT1A1 intermediate metaboliser genotype and other risk factors in patients treated with irinotecan-containing chemotherapy
11.30	Sybrand Zielhuis - The role of dexamethasone route of administration in the dexamethasone-aprepitant drug-drug interaction
11.45	AK Bos - The relationship between lenvatinib exposure and drug limiting toxicities in patients with differentiated thyroid carcinoma and renal cell carcinoma

Session 3	Renal – Room C3
11.00	IA Janssen - Cystatin C and creatinine-based eGFR in the inpatient and outpatient population
11.15	Ferdi Sombogaard - Incidence and Pharmacokinetic Predictors of Acute Kidney Injury During Vancomycin–Piperacillin/Tazobactam Therapy
11.30	Charlotte Stein - Risk of acute kidney injury after short-term metamizole use in real-world data
11.45	David Wolthuis - Model-informed repurposing of eliglustat for treatment and prophylaxis of Shiga toxin producing Escherichia coli hemolytic-uremic syndrome (stec-hus) in children

Session 4	A broader clinical pharmacology perspective – Room C2
------------------	--

11.00	Jette van Lint - Serious fungal urinary tract infections with SGLT2-inhibitors - a case series
11.15	Johannes Kroes - Paracetamol half-life declines over time after an acute overdose
11.30	ES Mense- The effect of eCDDS-based pharmacotherapeutic recommendations on the anticholinergic burden of hospitalized elderly patients
11.45	Michelle Mulder - Sex-specific outcomes in methotrexate therapy among patients with psoriatic arthritis and psoriasis

12.00 h Lunch – Restaurant

12.30 h General Meeting NVKF&B – Room C4/5

13.30 h Moderated poster sessions – Hallway by the lecture rooms

Link to abstracts (will be entered later)

14.30 h Parallel oral presentation session

Session 5	Anticoagulants & cardiovascular – Room C4/5
14.30	Ala Keyany - Effect of bariatric on direct anticoagulant (DOAC) drug levels
14.45	Stefan Teertstra - A Physiologically Based Pharmacokinetic Modelling approach to Optimize Therapeutic Nadroparin Dose Regimens in Paediatric Patients
15.00	Lieke Mitrov-Winkelmolen - Optimal dalteparin dose in obese patients - (The ODOP Study)
15.15	Tom Uyl - Carotid intima thickness and cardiovascular risk assessment in patients treated for head and neck cancer

Session 6	Oncology modelling– Room C2
14.30	Daan Lanser - Reducing lorlatinib-related toxicity by establishing the optimal exposure-toxicity threshold in patients with non-small cell lung cancer
14.45	Rob ter Heine - Translation modelling challenges receptor-occupancy-based dosing of PD-1 inhibitors like pembrolizumab
15.00	D van Asten - Population pharmacokinetics of [177Lu]Lu-PSMA combined with EBRT and ADT in treatment naïve patients: differences in clearance and cycle-dependent effects
15.15	Lieke Geschiere - Trastuzumab in pregnant women with breast cancer: a physiologically based pharmacokinetic model

15.30 h Break – Restaurant

15.50 h Plenary session

Session 7	Prize ceremony – C4/5
15.50 h	NVKFB Thesis Award Ceremony + presentation winner
16.10 h	NVKFB TOP Publication Award ceremony + presentation winner
16.30 h	NVKFB Best poster prize & NVKFB teaching price

16:40 h Drinks and networking – Restaurant